Report covers; Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines

1. www.visiongain.com
Page 94
Global Allergic Rhinitis Drugs Market 2018-2028
Oral Antihistamines, Intranasal Corticosteroids, Intranasal
Antihistamines, Immunotherapy and Vaccines
Figure 5.5 The Global Intranasal Corticosteroids Market by Leading
Drugs: Market Share (%), 2028
5.3 Leading Intranasal Corticosteroids
5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone
propionate) - GlaxoSmithKline
Flixonase and Flonase are nasal spray formulations of fluticasone propionate and are approved for
the treatment of allergic rhinitis in adults and children aged 2 years and over. Flonase is the US
brand name while Flixonase is the brand name in other markets. Sales have been in decline since
the launch of generic fluticasone in 2006. Generic competition followed a two-year period in which
GSK successfully delayed the launch of Roxane Laboratories’ generic fluticasone through several
tactics including filing citizen petitions with the FDA (before this practice was restricted in 2007). In
its 2013 report, GSK announced that it had settled antitrust litigation with buyers of Flonase in
settlements worth a total of $195m.
Flixonase/Flonase
/Flonase OTC
30.7%
Nasonex
2.2%
Avamys/Veramyst
0.4%
Rhinocort
1.5%
Nasacort/Nasacort
OTC
2.5%
Omnaris
1.0%
Beconase/Beconas
e AQ
0.4%
Qnasl
1.1%
Zetonna
0.2%
Others
59.8%
Source: Visiongain 2018

2. www.visiongain.com
Page 129
Global Allergic Rhinitis Drugs Market 2018-2028
Oral Antihistamines, Intranasal Corticosteroids, Intranasal
Antihistamines, Immunotherapy and Vaccines
Figure 6.11 Ragwitek Forecast: Revenue ($m) and AGR (%),
2017-2028
6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales
Forecast 2018-2028
Table 6.10 and Figure 6.12 show Visiongain’s revenue forecast for other allergic rhinitis
immunotherapy products between 2017 and 2028. We forecast the market for other
immunotherapy products used in the treatment of allergic rhinitis to increase over the forecast
period. This segment of the market will increase from $690m in 2017 to reach $1,300.3m in 2028
(Table 6.10 and Figure 6.12). The uptake of products such as Alustal and other new products likely
to enter unto the market will aid growth over the forecast period.
Table 6.10 Other Allergic Rhinitis Immunotherapy Products Forecast:
Revenue ($m), AGR (%) and CAGR (%), 2017-2028
0.0
5.0
10.0
15.0
20.0
25.0
0.0
50.0
100.0
150.0
200.0
AGR(%)
Revenue($m)
Year
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Others($m) 690.0 760.0 820.0 879.0 928.0 978.0 1,028.0 1,080.0 1,132.0 1,185.0 1,237.0 1,300.3
AGR (%) 10.1 7.9 7.2 5.6 5.4 5.1 5.1 4.8 4.7 4.4 5.1
CAGR (%, 2017-2022 &2022-2028)
CAGR (%, 2017-2028)
7.2 4.9
5.9
Source: Visiongain 2018
Source: Visiongain 2018

3. www.visiongain.com
Page 244
Global Allergic Rhinitis Drugs Market 2018-2028
Oral Antihistamines, Intranasal Corticosteroids, Intranasal
Antihistamines, Immunotherapy and Vaccines
Figure 11.1 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs
Market, 2018
11.3.1 Power of Buyers
Many allergic rhinitis drugs are commercially available as OTC, so revenues are less influenced by
pricing and reimbursement regulations. However, many antihistamines and corticosteroids are of
similar efficacy, which increases the power of buyers. Cost pressures on healthcare budgets are
likely to increase the power of buyers during the forecast period, as healthcare providers set limits
on what drugs can be reimbursed and to what extent. Across the pharmaceutical market the
consolidation of distributors, wholesalers and pharmacies into larger groups is likely to increase the
power of buyers. Cost pressures on distributors are also being passed on to manufacturers.
11.3.2 Power of Suppliers
No significant examples of raw material supply problems were encountered during the research
process for this report. Within the pharmaceutical industry as whole, pharmaceutical companies
traditionally purchase high volumes of raw materials and keep excess manufacturing capacity in
Rivalry
Among
Competitors
[High]
Threat of New
Entrants
[Low]
Power of
Buyers
[Medium]
Threat of
Substitutes
[Low]
Power of
Suppliers
[Low]
Source: Visiongain 2018